Rubraca

Rubraca sheds positive light for PARP inhibitors in endometrial cancer
Clinical Trials Arena
Tue, 04/2/24 - 11:43 am
Rubraca
Clovis Oncology
endometrial cancer
clinial trials
FDA rejects Clovis' long-shot bid for approval of Rubraca
Fierce Pharma
Mon, 06/5/23 - 11:29 am
Clovis Oncology
Rubraca
FDA
bankruptcy
Clovis sells off remaining assets—including cancer drug Rubraca—for $70M-plus
Fierce Pharma
Mon, 04/10/23 - 11:28 am
Clovis Oncology
Rubraca
bankruptcy
Pharma & Schweiz
Amid bankruptcy, Clovis reveals more regulatory troubles for Rubraca
Fierce Pharma
Mon, 02/13/23 - 10:48 am
Clovis Oncology
Rubraca
ovarian cancer
bankruptcy
In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use
Fierce Pharma
Mon, 12/5/22 - 11:07 am
Clovis Oncology
Rubraca
FDA
ovarian cancer
With the walls closing in for Clovis, FDA demands ovarian cancer restriction for Rubraca
Fierce Biotech
Thu, 11/17/22 - 10:52 am
Clovis Oncology
Rubraca
ovarian cancer
FDA
Clovis Oncology flags possible bankruptcy in 'very near term'
NASDAQ
Wed, 11/9/22 - 10:47 am
Clovis Oncology
bankruptcy
Rubraca
As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win
Fierce Pharma
Mon, 10/3/22 - 11:30 pm
Clovis Oncology
Rubraca
ovarian cancer
prostate cancer
Undeterred by FDA warning, desperate Clovis seeks Rubraca nod in front-line ovarian cancer
Fierce Pharma
Wed, 09/14/22 - 09:47 am
Clovis Oncology
Rubraca
FDA
ovarian cancer
Clovis, in need of cash or deals now to stem looming financial challenges, looks to pipeline for ideas
Fierce Biotech
Tue, 08/9/22 - 06:29 am
Clovis Oncology
Rubraca
ovarian cancer
funding
Why Clovis Oncology Stock Went Into Retreat Mode This Week
Motley Fool
Fri, 07/15/22 - 10:39 am
Clovis Oncology
Rubraca
ASCO: Clovis CEO defends Rubraca's ovarian cancer win as FDA wants more assurance
Fierce Pharma
Mon, 06/6/22 - 09:57 am
ASCO 2022
Clovis
Rubraca
ovarian cancer
FDA
Clovis quietly unveils crippling FDA delay as its troubles deepen
Fierce Pharma
Fri, 05/6/22 - 11:05 am
Clovis Oncology
FDA
Rubraca
ovarian cancer
Clovis equity investors overlook two elephants
EP Vantage
Fri, 04/1/22 - 10:27 am
Clovis Oncology
Rubraca
ovarian cancer
ASCO-GU – prostate cancer PARPS move to the front line
EP Vantage
Sun, 02/20/22 - 11:44 am
prostate cancer
ASCO-GU
PARP inhibitors
Lynparza
Zejula
Rubraca
Talzenna
biomarkers
AstraZeneca
Merck
GSK
JNJ
Clovis Oncology
Why Clovis Oncology Shares Got a Bump This Week
Motley Fool
Sat, 08/28/21 - 08:55 pm
Clovis Oncology
earnings
Rubraca
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer
Pharmaceutical Business Review
Thu, 06/11/20 - 11:16 am
Clovis Oncology
clinical trials
Rubraca
ovarian cancer
Opdivo
Bristol-Myers Squibb
Clovis steals march on AZ with PARP prostate approval
Pharmaforum
Mon, 05/18/20 - 10:44 am
Clovis Oncology
prostate cancer
Rubraca
FDA
From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now
Motley Fool
Thu, 05/7/20 - 10:46 am
FDA
drug approvals
Gilead Sciences
remdesivir
AstraZeneca
Merck
Lynparza
Clovis Oncology
Rubraca
Bristol-Myers Squibb
Opdivo
Yervoy
Positive Prostate Cancer Results for Lynparza Are Bad News for Clovis Oncology
Motley Fool
Mon, 04/27/20 - 07:27 pm
Clovis Oncology
Rubraca
AstraZeneca
Merck
Lynparza
prostate cancer

Pages